semaglutide and crohn's disease & Disease: Safety & IBD Considerations – PlexusDx GLP-1 Use in Crohn's Disease:

The oral GLP-1 market size in 2025 was US$ 6.81 billion, expected to grow to US$ 9.19 billion in 2026 and further to US$ 137.36 billion by 2035, backed by a robust CAGR of 35.05% between 2026 and 2035

The best choice is one that you can stick with consistently and that fits your lifestyle and health goals

Here are the main mechanisms: They boost insulin secretion after meals (but in a glucosedependent way, meaning they act more when blood sugar is higher)

It helps relax and contract muscles in the GI tract, keeping things moving without the cramping or urgency

Providers pay particular attention to indicators of inflammation, signs of insulin resistance, and hormone-related symptoms associated with conditions like PCOS, menopause, or autoimmune disorders

The body is adapting to lower energy intake